Hangzhou's AnHeart Completes $14.6 Million A Funding from Decheng

22:24 EDT 17 May 2019 | ChinaBio Today

AnHeart Therapeutics of Hangzhou raised $14.6 million in a Series A round from Decheng Capital, a China life science investor. AnHeart uses its expertise in global clinical development to develop innovative products, which it partners at near-term value inflection points. In late 2018, AnHeart in-licensed global rights to an oral, highly selective ROS1/NTRK small molecule inhibitor from Daiichi Sankyo. AB-106 is in two Phase I clinical trials in the US and Japan. After the Phase I trial, AnHeart will assume responsibility for further clinical development. More details....

Share this with colleagues:

Original Article: Hangzhou's AnHeart Completes $14.6 Million A Funding from Decheng


More From BioPortfolio on "Hangzhou's AnHeart Completes $14.6 Million A Funding from Decheng"

Quick Search


Relevant Topics

Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...